title: Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
abstract: Overactive AMPA receptor-mediated transmission may be involved in the pathogenesis of levodopa-induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor-mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP-lesioned marmoset model of Parkinson's disease and levodopa-induced dyskinesia. Topiramate significantly reduced levodopa-induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa-induced dyskinesia in patients with Parkinson's disease.
authors.affiliation: Department of Neurology, Hope Hospital, Salford, Manchester, United Kingdom.|Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester, United Kingdom.
authors.forename: Monty A
authors.initials: MA
authors.lastname: Silverdale
authors.affiliation: Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester, United Kingdom.
authors.forename: S L
authors.initials: SL
authors.lastname: Nicholson
authors.affiliation: Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester, United Kingdom.|Motac Neuroscience Ltd., Williams House, Manchester Science Park, Manchester, United Kingdom.
authors.forename: A R
authors.initials: AR
authors.lastname: Crossman
authors.affiliation: Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.
authors.forename: J M
authors.initials: JM
authors.lastname: Brotchie
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002144:Callithrix; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology*; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007980:Levodopa / Q000008:administration & dosage / Q000627:therapeutic use*; D020267:MPTP Poisoning / Q000150:complications*; D010300:Parkinson Disease / Q000188:drug therapy*; D000077236:Topiramate
chemical_list: D000927:Anticonvulsants; D000978:Antiparkinson Agents; D000077236:Topiramate; D005632:Fructose; D007980:Levodopa